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Introduction
Since the World Health Organization WHO endorsement of Xpert MTB/RIF in December 2010 and its subsequent recommendation to health authorities to roll-out the technology in phases within the context of national plans, many high Tuberculosis (TB) burden countries have embarked on implementing the technology to improve the management of TB [1] . Xpert allows a rapid diagnosis of TB and a presumptive diagnosis of multi drug resistant TB (MDR TB) without requiring the comparatively sophisticated laboratory facilities and complex methodologies of other established tests such as culture and line probe assays.
In addition to the capital equipment expenditure and recurrent costs for the cartridges and calibrating machines [2] , there are costs associated with upgrading laboratories to receive the new Xpert MTB/RIF machines. These costs are likely to be inversely proportional to the strength of the laboratory infrastructure and to vary across locations [3] . This information however is critical when an institution is planning the introduction of Xpert, and an estimate of the likely costs will inform scale-up decisions. While there are large numbers of studies on the accuracy of Xpert, there is no literature describing the costs associated with its installation in resource -limited settings [4] . WHO in its 2012 global TB report ranked Nigeria as the country with the 10th highest burden of TB with characteristics of a low resource setting [5] . The Federal Capital Territory (FCT) TB and Leprosy Control Programme (TBLCP) was established in 1992 and currently provides 39 treatment and 22 diagnostic centers. In 2012 it diagnosed 2111 patients but, despite a rapid expansion since inception, the case detection rate is still low (at 58%) and below the Nigerian target of 70%. In 2010, the FCT TBLCP purchased 5 new Xpert machines as part of a programme to increase case detection.
The study presented the opportunity to describe the costs associated with the introduction of Xpert in selected district hospitals within this context.
Methods
Five four-module Xpert instruments were received by the FCT- The project developed a network of community health extension workers who conducted house-to-house visits to identify adults with symptoms of TB and motorbike riders who linked the teams to the laboratory facilities by transporting specimens. Patients were tested using smear-microscopy and smear-negative patients were further tested with Xpert using an interim diagnostic algorithm. The management of the patients was conducted by the programme using its treatment algorithms [6] .
During its planning phase, the project assessed the LAC hospital laboratories that routinely conducted smear microscopy to select those considered to have suitable facilities for the introduction of 
Results
A wide range of costs were incurred during the installation of the instruments. Some of these problems were not foreseen before initiating the project and costs often snowballed due to variety of reasons. For example, despite the survey, it was soon recognized that the electricity backup system provided by the hospitals still allowed short electricity interruptions before a generator re-instated the supply. In turn, the extra equipment needed to secure uninterrupted electrical supply required additional laboratory space.
The main basic costs incurred to install the machines in the laboratories are described in Table 1 In two laboratories we purchased generators because the hospitals' own generators were broken. The electrical equipment (invertors, batteries etc) was bulky and required more space than anticipated and was not possible to accommodate them within the laboratory premises. It became evident that the added equipment overwhelmed the laboratory and could not be accommodated into the existing premises.
We therefore purchased and furnished cargo containers to provide additional bench, storage and office space. Refurbishment included air conditioners, as temperatures are usually >30oC. The costs for the sites requiring additional premises are shown inTable 2. These additional costs ranged from $2,621.98 to $9,716.21.
Discussion
The WHO technical and operational guidance on Xpert [2] provides annual itemized budget calculations [4] per site, which is considerably more expensive that the guidance estimates. Conversely, the cost of training was lower in our case (USD 2,605.19), than the guidance estimate of USD 5,000, which was due to the availability of in-house expertise for installation and training.
Finding the space required for the machines was a common problem, with the FCT health and human services having no space in two sites to build or expand the existing laboratories and competing priorities from other projects and programmes.
Consequently, with the need to implement the project as quickly as possible, the procurement of cargo containers was the only option available to us. This added, on average, an additional USD 6,792.31 per site. Studies looking at the cost effectiveness of Xpert in India, South Africa and Uganda reported variations in the infrastructure cost [3, 7, 8] . Although the studies did not detail the reasons for these differences, they are likely to reflect the national laboratory infrastructure and the level of the health system where they are placed (tertiary or secondary).
Conclusion
Our findings in Abuja demonstrate that countries need to carefully 
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